Search

Pivotal Ruxolitinib Data Shows Promise for Patients with PV.

 

Polycythemia vera (PV) is a chronic, incurable blood cancer with limited treatment options. If uncontrolled, PV can cause serious cardiovascular complications, such as stroke and heart attack.

Read more

Publications

Ruxolitinib for the management of myelofibrosis: Results of an international physician survey. Ellis MH, Koren-Michowitz M, Lavi N, Vannucchi AM, Mesa R, Harrison CN. Leuk Res. 2017 Oct;61:6-9. doi: 10. 1016/j. leukres. 2017. 08. 002.

Read more

EHA-BMSH Balkan Hematology Tutorial

EHA is joining the Bulgarian Medical Society of Hematology (BMSH) to organize the EHA-BMSH Balkan Hematology Tutorial on Myeloproliferative disorders.

Read more

SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML

Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.

Read more

Does the patient with myelofibrosis feel better through Pacritinib?

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Read more

Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes

Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes

Chronic lymphocytic leukemia (CLL) with the deletion of chromosome 17p (del17p) has been linked to aggressive disease and patient survival of only…

Read more

Selected EMA news

December 2024New information on approved medicines
Sarclisa (isatuximab) - new indication
Treatment of multiple myeloma (a type of blood cancer)
Withdrawal of applications for extension of indication
Inaqovi (cedazuridine / decitabine)
Treatment of different types of blood cancer
Direct Healthcare Professional Communication (DHPC)
Pegasys (peginterferon alfa-2a)
Treatment of…

Read more

EHA Statement of Solidarity with Ukraine

The European Hematology Association (EHA) is deeply concerned about the situation in Ukraine, the plight of the civilian population, and the damage to healthcare infrastructures.

Read more